Seeking Alpha
 

United Therapeutics Corporation (UTHR)

- NASDAQ
  • Aug. 29, 2014, 12:45 PM
    | Comment!
  • Aug. 29, 2014, 11:52 AM
    • Shares of United Therapeutics (UTHR +23.1%) jump on 5x surge in volume after a court rules that Sandoz (NVS +0.3%) failed to prove that United's '007 and '117 Remodulin (treprostinil) patents are invalid and that United proved that Sandoz's ANDA will infringe on patent '117.
    • Remodulin accounted for almost 45% of United's 1H sales of $612.2M.
    | Comment!
  • Dec. 23, 2013, 5:35 PM
    • Supernus Pharmaceuticals (SUPN) shares spike 24%, adding to an 8% gain in regular trading, after the company announces the FDA has approved Orenitram extended-release tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.
    • The news broke last week, but it appears that investors have had in their memory that Supernus has a development/licensing agreement for the drug with United Therapeutics jolted by the PR.
    • Supernus developed the formulation under an agreement with United Therapeutics (UTHR +30.4%), whose shares rocketed when the approval was announced earlier today. United will pay Supernus certain milestone fees and royalties on global product sales.
    | 1 Comment
  • Dec. 23, 2013, 12:46 PM
    | Comment!
  • Dec. 23, 2013, 9:50 AM
    • Sarepta Therapeutics (SRPT +3.7%upgraded to Neutral from Underweight at Piper. Price target is $20.
    • United Therapeutics (UTHR +24.2%) upgraded to Outperform (from Market Perform) at BMO and to Neutral (from Underweight) at JPMorgan.
    • Surgical Care Affiliates (SCAI -1.1%) initiated at Outperform at BMO. Price target is $37.
    | Comment!
  • Dec. 23, 2013, 9:10 AM
    | Comment!
  • Apr. 25, 2013, 3:46 PM
    United Therapeutics (UTHR -3%) slides after its Q1 EPS results missed Street expectations earlier today. Revenue increased by nearly $41M over the prior year the period, with growth in product revenues reflecting the continuing increase in the number of patients being treated, but expenses in both R&D and SG&A pressured bottom line performance.
    | Comment!
  • Apr. 11, 2013, 11:15 AM
    United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells.
    | 1 Comment
  • Mar. 25, 2013, 9:10 AM
    Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%
    | Comment!
  • Mar. 25, 2013, 6:11 AM
    The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating for high blood pressure. United Therapeutics intends to immediately request an "end of review" meeting with the FDA to discuss the rejection. Shares -6.3% premarket. (previous) (PR)
    | Comment!
  • Feb. 26, 2013, 1:26 PM
    After a valliant fight, United Therapeutics (UTHR -0.9%) gives up the days gains to trade in the red after Brean Murray cuts the shares to Hold on the back of its Q4 results posted earlier. The stock has had a good run since plummeting in October of last year on the FDA's rejection of Treprostinil, gaining nearly 30% and presently testing a 2-year high.
    | Comment!
  • Feb. 4, 2013, 11:17 AM
    United Therapeutics (UTHR +1.3%) moves up after its board authorizes an additional $420M to its existing share repurchase program. The program will become effective on March 4 and remain open for up to one year. Separately, Standpoint Research ups the shares from Hold to Buy.
    | Comment!
  • Oct. 24, 2012, 12:45 PM
    Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%.
    | Comment!
  • Oct. 24, 2012, 9:10 AM
    Premarket gainers: SEH +62%. FB +26%. RFMD +14%. LL +13%. RENN +11%. POL +10%. DOW +6%. ZNGA +5%. GRPN +5%. MM +6%.
    Losers: TPX -21%. NFLX -18%. DSCO -14%. UTHR -12%. INVN -8%. KMT -7%. XOMA -7%.
    | Comment!
  • Oct. 24, 2012, 8:25 AM
    United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the company's new drug application for treprostinil, an oral treatment for high blood pressure. The agency is uncertain whether another study would help change its mind, but said that if UTHR does decide on a further trial, it should consider a fixed dose design and more frequent dosing. (PR)
    | 1 Comment
  • Oct. 23, 2012, 5:40 PM
    After-hours top gainers, as of 5:15 p.m.: RFMD +12%; TWIN +9.2%; FB +8.2%; IDIX +6.5%; PNRA +6.4%.
    After-hours top losers: INVN -19.1%; TPX -18.4%; IRBT -15.2%; BWLD -10.2%; UTHR -9.9%.
    | 1 Comment
Visit Seeking Alpha's
UTHR vs. ETF Alternatives
Company Description
United Therapeutics Corp is a biotechnology company. The Company is engaged in thedevelopment and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.